The Relationship between Serum Bimarkers with the Results of Down Syndrome Screening and Fetal Karyotype in High Risk Pregnant Women Relationship Some serum biochemical markers with the results of first trimester Down syndrome screening
Advances in Nursing & Midwifery,
دوره 31 شماره 3 (2022),
15 ژوئیهٔ 2022
,
صفحه 32-38
https://doi.org/10.22037/anm.v31i3.39828
چکیده
Abstract
Introduction: Considering the many problems of a child with Down syndrome, early diagnosis allows parents to prepare for the birth and care of these children or to suggest termination of pregnancy. This study aimed to investigate associations between serum levels of folic acid and Superoxide dismutase (SOD1) with the results of the first trimester Down syndrome screening and fetal karyotype in high-risk pregnant women.
Methods: In this cross-sectional study, 232 women with high-risk pregnancies who had positive Down syndrome screening and undergone amniocentesis were selected through purposive sampling at the gestational age of 14-20 weeks. After obtaining an informed written consent form, the questionnaires related to the research were filled and the information on NT ultrasound and biochemical screening tests was extracted from the patients’ files. We measured serum levels of folic acid and SOD1 in all participants using the ELISA method. Statistical analysis was done by applying a multivariate logistic regression model by backward strategy. The Hosmer-Lemeshow test was utilized for better goodness of fit for the logistic regression model. In this study, p-value of <0.05 was considered statistically significant.
Results: In our study, 97% of participants consumed folic acid, serum level measurements revealed, 6.9% of participants had low folic acid levels, and 5.6% of Down syndrome positive screenings had a positive karyotype. The mean (SD) serum levels of superoxide dismutase enzyme (SOD-1) measured in the present study in the participants was 297.40 (75.55) U/ml. There were no significant relationship between serum levels of folic acid [odds ratio (OR) (95% CI): 0.125 (0.001 to 31.42); P=0.461] and SOD1 levels [OR (95% CI): 0.99 (0.976 to 1.01); P=0.799] with fetal karyotype results (P>0.05).
Conclusions: These findings demonstrate that serum folic acid and SOD1 concentration is not the predictive markers of Down syndrome karyotype in high-risk pregnant women who have positive Down syndrome screening through a double marker test.
- Down Syndrome
- Folic Acid
- Superoxide Dismutase-1 (SOD1)
ارجاع به مقاله
مراجع
Hu H, Jiang Y, Zhang M, Liu S, Hao N, Zhou J, et al. A prospective clinical trial to compare the performance of dried blood spots prenatal screening for Down's syndrome with conventional non-invasive testing technology. Exp Biol Med (Maywood). 2017;242(5):547-53. doi: 10.1177/1535370216683837 pmid: 28056555
Ke WL, Zhao WH, Wang XY. Detection of fetal cell-free DNA in maternal plasma for Down syndrome, Edward syndrome and Patau syndrome of high risk fetus. Int J Clinic Experiment Med. 2015;8(6):9525-30.
Gekas J, Langlois S, Ravitsky V, Audibert F, van den Berg DG, Haidar H, et al. Non-invasive prenatal testing for fetal chromosome abnormalities: review of clinical and ethical issues. Appl Clin Genet. 2016;9:15-26. doi: 10.2147/TACG.S85361 pmid: 26893576
Bull MJ. Down Syndrome. N Engl J Med. 2020;382(24):2344-52. doi: 10.1056/NEJMra1706537 pmid: 32521135
Down syndrome. 2013. Available from: https://meshb.nlm.nih.gov/record/ui?ui=D004314.
Nicolaides KH, Syngelaki A, Gil M, Atanasova V, Markova D. Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. Prenat Diagn. 2013;33(6):575-9. doi: 10.1002/pd.4103 pmid: 23613152
Zampieri BL, Biselli JM, Goloni-Bertollo EM, Vannucchi H, Carvalho VM, Cordeiro JA, et al. Maternal risk for Down syndrome is modulated by genes involved in folate metabolism. Dis Markers. 2012;32(2):73-81. doi: 10.3233/DMA-2011-0869 pmid: 22377700
Kedar R, Chandel D. MTHFR gene polymorphism and associated nutritional deficiency in the etiology and pathogenesis of Down syndrome. Egypt J Med Human Gen. 2019;20(1):1-10. doi: 10.1186/s43042-019-0010-9
Folic acid. 2016. Available from: https://meshb.nlm.nih.gov/record/ui?ui=D005492.
Coppede F. Risk factors for Down syndrome. Arch Toxicol. 2016;90(12):2917-29. doi: 10.1007/s00204-016-1843-3 pmid: 27600794
Boduroglu K, Alanay Y, Koldan B, Tuncbilek E. Methylenetetrahydrofolate reductase enzyme polymorphisms as maternal risk for Down syndrome among Turkish women. Am J Med Genet A. 2004;127A(1):5-10. doi: 10.1002/ajmg.a.20432 pmid: 15103709
Takamura N, Kondoh T, Ohgi S, Arisawa K, Mine M, Yamashita S, et al. Abnormal folic acid-homocysteine metabolism as maternal risk factors for Down syndrome in Japan. Eur J Nutr. 2004;43(5):285-7. doi: 10.1007/s00394-004-0472-4 pmid: 15309447
Green NS. Folic acid supplementation and prevention of birth defects. J Nutr. 2002;132(8 Suppl):2356S-60S. doi: 10.1093/jn/132.8.2356S pmid: 12163692
Ferrari M, Stagi S. Oxidative Stress in Down and Williams-Beuren Syndromes: An Overview. Molecules. 2021;26(11). doi: 10.3390/molecules26113139 pmid: 34073948
Perrone S, Longini M, Bellieni CV, Centini G, Kenanidis A, De Marco L, et al. Early oxidative stress in amniotic fluid of pregnancies with Down syndrome. Clin Biochem. 2007;40(3-4):177-80. doi: 10.1016/j.clinbiochem.2006.10.019 pmid: 17208212
Bahsi S, Bakır A, Topçu V, Bahsi T, Ergüder Bİ. Evaluation of Oxidant/Antioxidant System, IL-6 and IL-10 Parameters and SOD-Enzyme Activity in Pregnancy with Down Syndrome in Amnion Fluid Analysis. GMJ. 2022;33:53-7. doi: 10.12996/gmj.2022.12
Nachvak SM, Ahani Kamangar S. Stress Oxidative in Down Syndrome : Mechanisms, Managements. J Except Child. 2011;11(3).
Duncan TM, Reed MC, Nijhout HF. The relationship between intracellular and plasma levels of folate and metabolites in the methionine cycle: a model. Mol Nutr Food Res. 2013;57(4):628-36. doi: 10.1002/mnfr.201200125 pmid: 23143835
Baggot PJ, Eliseo AJ, DeNicola NG, Kalamarides JA, Shoemaker JD. Organic acid concentrations in amniotic fluid found in normal and Down syndrome pregnancies. Fetal Diagn Ther. 2008;23(3):245-8. doi: 10.1159/000116749 pmid: 18417986
Baluja-Conde IB, Rodríguez-López MR, Zulueta-Rodríguez O, Ruiz-Escandón B, Bermúdez-Velásquez S. Biochemical serum markers for Down syndrome screening. Rev Biomed. 2005;16(4):259-72. doi: 10.32776/revbiomed.v16i4.427
Trissler RJ. Folic acid and Down syndrome. J Am Diet Assoc. 2000;100(2):159. doi: 10.1016/s0002-8223(00)00048-1 pmid: 10691390
Hollis ND, Allen EG, Oliver TR, Tinker SW, Druschel C, Hobbs CA, et al. Preconception folic acid supplementation and risk for chromosome 21 nondisjunction: a report from the National Down Syndrome Project. Am J Med Genet A. 2013;161A(3):438-44. doi: 10.1002/ajmg.a.35796 pmid: 23401135
Ginani CTA, Luz J, Silva SVE, Coppede F, Almeida MDG. Association between MTHFR C677T and A1298C gene polymorphisms and maternal risk for Down syndrome: A protocol for systematic review and/or meta-analysis. Medicine (Baltimore). 2022;101(3):e28293. doi: 10.1097/MD.0000000000028293 pmid: 35060496
Coppede F. The genetics of folate metabolism and maternal risk of birth of a child with Down syndrome and associated congenital heart defects. Front Genet. 2015;6:223. doi: 10.3389/fgene.2015.00223 pmid: 26161087
Pennings JL, Imholz S, Zutt I, Koster MP, Siljee JE, de Vries A, et al. Predictive performance of a seven-plex antibody array in prenatal screening for Down Syndrome. Dis Markers. 2015;2015:519851. doi: 10.1155/2015/519851 pmid: 25983373
Zafrilla P, Cerda B, Soler A, Xandri J, Martinez-Cachá A, Mulero J. Oxidative stress in Down
- چکیده مشاهده شده: 372 بار
- pdf (English) دانلود شده: 155 بار